2024 Gastroesophageal Reflux Disease Therapeutics Market Report : Market Size, Growth Drivers, And Key Trends | Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc

"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Gastroesophageal Reflux Disease Therapeutics Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $7.33 billion In 2028 At A CAGR Of 5.1%.

The gastroesophageal reflux disease therapeutics market size has grown steadily in recent years. It will grow from $5.78 billion in 2023 to $6 billion in 2024 at a compound annual growth rate (CAGR) of 3.8%. The growth in the historic period can be attributed to changing lifestyles and dietary habits, aging population, increased awareness and diagnosis, prevailing stressful lifestyles, rise in obesity rates..

The gastroesophageal reflux disease therapeutics market size is expected to see strong growth in the next few years. It will grow to $7.33 billion in 2028 at a compound annual growth rate (CAGR) of 5.1%. The growth in the forecast period can be attributed to rise in demand for novel therapies, growing geriatric population, personalized medicine approaches, focus on non-pharmacological interventions, emergence of biologics and innovative therapies.. Major trends in the forecast period include alternative therapies and mind-body practices, expanded research into gut health, advent of patient-centric care models, targeted marketing for gerd awareness, integration of digital health tools..

Request A Sample Of This Report - https://www.thebusinessresearchcompany.com/sample.aspx?id=12058&type=smp

Gastroesophageal Reflux Disease Therapeutics Market Major Segments
The gastroesophageal reflux disease therapeutics market covered in this report is segmented -

1) By Type: Branded, Generic
2) By Drug Class: Antacids, Proton Pump Inhibitors, Histamine Blockers, Pro-Kinetic Agents, Other Drugs Class
3) By Distribution Channel: Hospital Pharmacy, Drug Stores, General Stores, Supermarkets
4) By Application: Crohn's Disease, Gastroesophageal Reflux Disease (GERD), Ulcerative Colitis

Key Driver - Surge In Gastroesophageal Reflux Disease Anticipated To Drive The Growth Of The Gastroesophageal Reflux Disease Therapeutics Market

The prevalence of gastroesophageal reflux disease is expected to propel the growth of the gastroesophageal reflux disease therapeutics market moving forward. Gastroesophageal reflux disease is a chronic condition characterized by the backflow of stomach acid into the esophagus, causing symptoms such as heartburn, regurgitation, and potential complications. The gastroesophageal reflux disease (GERD) therapeutics help in reducing and managing the symptoms of acid reflux by neutralizing the pH of the gut, controlling inflammation, and improving esophageal function. For instance, in September 2022, according to the article published by WebMed, a US-based online publisher of news and information about human health, more than 60 million American adults suffer heartburn at least once a month, and more than 15 million suffer daily. Furthermore, in July 2022, statistics shared by the National Library of Medicine, a US-based federal medical library, GERD is one of the most often diagnosed digestive illnesses in the United States, with a 20% prevalence, resulting in a significant economic burden in direct and indirect expenditures as well as a negative impact on quality of life. Therefore, the prevalence of gastroesophageal reflux disease is expected to drive the growth of the gastroesophageal reflux disease therapeutics market.

Customise This Report As Per Your Requirements - https://www.thebusinessresearchcompany.com/Customise?id=12058&type=smp

Prominent Trend - Innovative Medications To Reshape The Gastroesophageal Reflux Disease Therapeutics Market

Product innovations are the key trend gaining popularity in the gastroesophageal reflux disease therapeutics market. Major companies operating in the gastroesophageal reflux disease therapeutics market are focusing on innovative medications to sustain their position in the market. For instance, in March 2021, Xiromed LLC, a US-based integrated generic company, launched Omeprazole Delayed-Release Capsules (generic to Prilosec) to treat frequent heartburn in gastroesophageal reflux. Omeprazole is a proton pump inhibitor (PPI) medication designed to treat some stomach and esophageal issues (such as acid reflux and ulcers) by lowering the quantity of acid produced by the stomach that alleviating symptoms such as heartburn, trouble swallowing, and persistent cough. This drug helps cure acid damage to the stomach and esophagus, prevents ulcers, and may help prevent oesophageal cancer.

Gastroesophageal Reflux Disease Therapeutics Market Players
Major companies operating in the gastroesophageal reflux disease therapeutics market report are Pfizer Inc., Johnson and Johnson, Novartis AG, Sanofi S.A., AstraZeneca plc, Medtronic PLC, GlaxoSmithKline plc, Eisai Co. Ltd., Takeda Pharmaceutical Company Limited, bioMerieux SA, Teva Pharmaceutical Industries, Dr. Reddy's Laboratories Ltd., Bruker Corp, Amneal Pharmaceuticals LLC, CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co. Ltd, Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Camber Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., EndoGastric Solutions, RaQualia Pharma Inc, TWi Pharmaceuticals Inc., Astellas Pharma Inc., SFJ Pharmaceuticals Group, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Limited, Addex Pharmacetuicals.

View The Full Report Here - https://www.thebusinessresearchcompany.com/report/gastroesophageal-reflux-disease-therapeutics-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the gastroesophageal reflux disease therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastroesophageal reflux disease therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Gastroesophageal Reflux Disease Therapeutics Market Report Structure
3. Gastroesophageal Reflux Disease Therapeutics Market Trends And Strategies
4. Gastroesophageal Reflux Disease Therapeutics Market - Macro Economic Scenario
5. Gastroesophageal Reflux Disease Therapeutics Market Size And Growth
…..
27. Gastroesophageal Reflux Disease Therapeutics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ "

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.